Matthew T Campbell, M.D., M.S.

Peer-Reviewed Articles

1. Goswami, S, Gao, J, Basu, S, Shapiro, DD, Karam, JA, Tidwell, RS, Ahrar, K, Campbell, M, Shen, Y, Trevino, AE, Mayer, AT, Espejo, A, Seua, C, Macaluso, M, Chen, Y, Liu, W, He, Z, Yadav, SS, Wang, Y, Rao, P, Zhao, L, Zhang, J, Jindal, S, Tannir, NM, Futreal, A, Wang, L, Sharma, P. Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma. Nature communications 16(1), 2025. e-Pub 2025. PMID: 39984485.
2. Beckermann KE, Shah NJ, Campbell MT, Haas NB, Nelson A, Ornstein MC, Mao S, Keshava-Prasad HS, Hammers H, Gao X, Gourdin T, George S, Hoimes CJ, Hussain A, Jonasch E, Rini BI, Voss MH. Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma. Oncologist 30(6), 2025. e-Pub 2025. PMID: 40549043.
3. Jackson, J, Sanchez, D, Joon, A, Estecio, MR, Johns, AC, Shah, AY, Campbell, M, Ward, JF, Pisters, LL, Guo, CC, Zhang, M, Millward, NZ, Tu, S. Bilateral Germ Cell Tumor of the Testis. Cells 14(9), 2025. e-Pub 2025. PMID: 40358182.
4. Stringam, J, Pal, K, Niekamp, AS, Jiwani, R, Paolucci, I, Kuban, JD, Metwalli, ZA, Huang, SY, Habibollahi, P, Chen, SR, Yevich, SM, Patel, MN, Subudhi, SK, Campbell, M, Ghia, AJ, Tatsui, CE, Sheth, RA. Safety, Efficacy, and Adjacent-level Fracture Risk Following Vertebral Augmentation and Radiofrequency Ablation for the Treatment of Spine Metastases in Patients with Cancer. Radiology: Imaging Cancer 7(3):e240122, 2025. e-Pub 2025. PMID: 40377420.
5. Hahn, AW, Adra, N, Vaishampayan, U, Xiao, L, Dizman, N, Yuan, Y, Mukhida, SS, Campbell, M, Gao, J, Zurita-Saavedra, A, Jonasch, E, Tannir, NM, Shah, AY, Msaouel, P. A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC. Oncologist 30(4), 2025. e-Pub 2025. PMID: 40212021.
6. Jindal, T, Jiang, C, Alhalabi, O, Nizam, A, Nguyen, CB, Talukder, R, Bakaloudi, DR, Davidsohn, M, Freeman, D, Glover, MJ, Khaki, AR, Evans, S, Lemke, EA, Bose, R, Sim, W, Pywell, C, Basu, A, Kilari, D, Barata, P, Bilen, MA, Zakharia, Y, Milowsky, MI, Shah, SA, Bellmunt, J, Grivas, PD, Emamekhoo, H, Davis, NB, Gupta, S, Hoimes, C, Campbell, M, Alva, A, Koshkin, VS. Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma. European Urology Oncology 8(2):258-262, 2025. e-Pub 2025. PMID: 39709257.
7. Choueiri TK, Penkov K, Uemura H, Campbell MT, Pal S, Kollmannsberger C, Lee JL, Venugopal B, van den Eertwegh AJM, Negrier S, Gurney H, Albiges L, Berger R, Haanen JBAG, Oyervides Juarez V, Rini BI, Larkin J, Nole F, Schmidinger M, Atkins MB, Tomita Y, Ellers-Lenz B, Hoffman J, Sandner R, Wang J, di Pietro A, Motzer RJ. Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial. Ann Oncol 36(4):387-392, 2025. e-Pub 2025. PMID: 39706335.
8. Campbell MT, Jackson JC, Sanchez D, Joon AY, Estecio MR, Johns AC, Shah AY, Campbell MT, Ward JF, Louis L, Pisters, Guo CC, Zhang M, Zacharias NM, Tu S. Bilateral Germ Cell Tumor of the Testis: Biological and Clinical Implications for a Stem versus Genetic Origin of Cancers. Cells. e-Pub 2025.
9. Berg, S, La Rosa, S, Zhang, T, Pierorazio, P, Albiges, L, Beckermann, KE, Campbell, M, Carlo, MI, Coleman, K, George, DJ, Geynisman, DM, Johnson, R, Jonasch, E, Maranchie, J, McGregor, BA, Shapiro, DD, Singer, EA, Shuch, B, Stadler, WM, Tannir, NM, Zakharia, Y, Vaishampayan, U, Thall, PF, Msaouel, P. Impact of postprogression therapies on overall survival. Urologic Oncology: Seminars and Original Investigations 43(3):135-146, 2025. e-Pub 2025. PMID: 39500687.
10. Moussa, MJ, Khandelwal, J, Wilson, NR, Malikayil, KL, Surasi, DS, Bathala, TK, Lin, Y, Rao, P, Tamboli, P, Sircar, K, Ajufo, HO, Elsayes, KM, Shah, AY, Johns, AC, Goswami, S, Hasanov, E, Jonasch, E, Msaouel, P, Campbell, M, Alhalabi, O, Tannir, NM. Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma. Journal for immunotherapy of cancer 13(2), 2025. e-Pub 2025. PMID: 39939142.
11. Moussa, MJ, Tabet, GC, Siefker-Radtke, AO, Xiao, L, Wilson, NR, Gao, J, Logothetis, CJ, Grivas, PD, Lee, B, Shah, AY, Msaouel, P, Li, R, Clemente, LC, Zhao, J, Tannir, NM, Kamat, A, Hansel, DE, Guo, CC, Campbell, M, Alhalabi, O. Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract. Cancer medicine 14(2), 2025. e-Pub 2025. PMID: 39831734.
12. Wang E, Rupe ES, Mukhida SS, Johns AC, Campbell MT, Shah AY, Zurita AJ, Gao J, Goswami S, Jonasch E, Msaouel P, Tannir NM, Hahn AW. Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma. Eur Urol Focus 11(1):150-158, 2025. e-Pub 2025. PMID: 39307587.
13. Gajagowni S, Wang E, Wang J, Campbell MT, Siddiqui BA. Hemophagocytic Lymphohistiocytosis (HLH) Following Immune Checkpoint Therapy (ICT). Case Rep Oncol Med 2025:5582848, 2025. e-Pub 2025. PMID: 39816730.
14. El Zarif T, Semaan K, Xie W, Eid M, Zarba M, Issa W, Zhang T, Nguyen CB, Alva A, Fahey CC, Beckermann KE, Karam JA, Campbell MT, Procopio G, Stellato M, Buti S, Zemankova A, Melichar B, Massari F, Mollica V, Venugopal B, Ebrahimi H, de Velasco G, Gurney HP, De Giorgi U, Parikh O, Winquist E, Master V, Garcia AR, Cutuli HJ, Ferguson TR, Gross-Goupil M, Baca SC, Pal SK, Braun DA, McKay RR, Heng DYC, Choueiri TK. First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study. Eur Urol 86(6):503-512, 2024. e-Pub 2024. PMID: 39147674.
15. Xiang, JJ, Campbell, M, Tu, S, Araujo, JC, Nieto, Y, Lin, JK, Xiao, L, Shah, AY, Wang, J. Doxorubicin, Paclitaxel, and Cisplatin (ATP) for Relapsed/Refractory Germ Cell Tumors. Clinical Genitourinary Cancer 22(6), 2024. e-Pub 2024. PMID: 39532049.
16. Tabet, GC, Zheng, L, Hosseini, H, Ward, JF, Pisters, LL, Campbell, M, Tu, S, Czerniak, BA, Guo, CC. Epithelioid trophoblastic tumor in male patients with germ cell tumor. Human Pathology 153, 2024. e-Pub 2024. PMID: 39461379.
17. Chahla B, Pal K, Balderrama-Brondani V, Yaylaci F, Campbell MT, Sheth RA, Habra MA. Clinical outcomes of image-guided therapies in patients with adrenocortical carcinoma: a tertiary referral center retrospective study. Oncologist 29(10):850-858, 2024. e-Pub 2024. PMID: 38869364.
18. Shanker MD, Yu ZH, Yang J, Matin S, Campbell MT, Msaouel P, Tannir N, Prajapati S, Ding Y, Lee B, Sobremonte A, Tang C. MR-Linac-guided stereotactic radiotherapy for CT-indiscernible intravascular renal cell carcinoma tumours. BJUI Compass 5(10):913-915, 2024. e-Pub 2024. PMID: 39416759.
19. Maksimovic S, Boscolo NC, La Posta L, Barrios S, Moussa MJ, Gentile E, Pesquera PI, Li W, Chen J, Gomez JA, Basi A, Burks JK, Alvarez-Breckenridge C, Gao J, Dondossola E, Campbell MT. Antiangiogenic tyrosine kinase inhibitors have differential efficacy in clear cell renal cell carcinoma in bone. Cancer Res Commun, 2024. e-Pub 2024. PMID: 39248577.
20. Li YJ, Msaouel P, Campbell MT, Hwu P, Diab A, Kim ST. Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series. RMD Open 10(3), 2024. e-Pub 2024. PMID: 39214611.
21. Campbell MT, Shah AY, Msaouel P, Tannir NM, Siefker-Radtke AO, Kamat AM, Navai N, Dinney CPN, Rao P, Guo CC, Sheth RA, Venkatesan AM, Tidwell RS, Yadav SS, Gu A, Chen H, Macaluso M, Duan F, Basu S, Jindal S, Sharma P. A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle Invasive Bladder Cancer. Cancer Res Commun, 2024. e-Pub 2024. PMID: 39207194.
22. Shanker MD, Yu ZH, Yang J, Matin S, Campbell MT, Msaouel P, Prajapati S, Ding Y, Lee B, Sobremonte A, Tang C. MR-Linac-guided stereotactic radiotherapy for CTindiscernible intravascular renal cell carcinoma tumours. e-Pub 2024.
23. Laganà M, Balderrama-Brondani V, Herrera KR, Chahla B, Yaylaci F, Bassett RL, Jimenez C, Varghese J, Waguespack SG, Campbell MT, Shah AY, Rojas Hernandez CM, Habra MA. Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis. Oncologist 29(7):575-580, 2024. e-Pub 2024. PMID: 38776552.
24. Johns AC, Campbell MT, Gao M, Hahn AW, Lim Z, Wang E, Gao J, Shah AY, Msaouel P, Tannir NM. Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma. Oncologist 29(7):589-595, 2024. e-Pub 2024. PMID: 38478923.
25. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 15(1):5621, 2024. e-Pub 2024. PMID: 38965214.
26. Moussa MJ, Khandelwal J, Wilson NR, Naik SA, Subbiah V, Campbell MT, Msaouel P, Singh P, Alhalabi O. Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. Curr Oncol 31(6):3342-3349, 2024. e-Pub 2024. PMID: 38920737.
27. Matin SF, Adibi M, Shah AY, Alhalabi O, Paul C, Guo C, Amirtharaj R, Xiao L, Lange S, Duose DY, Wang S, Pal S, Campbell MT. Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma. The Journal of Urology 211(6). e-Pub 2024.
28. Jackson, J, Sanchez, D, Johns, AC, Campbell, M, Aydin, AM, Gokden, N, Maraboyina, S, Muesse, JL, Ward, JF, Pisters, LL, Millward, NZ, Guo, C, Tu, S. Germ Cell Tumor of the Testis. Journal of Clinical Medicine 13(12), 2024. e-Pub 2024. PMID: 38929965.
29. Jackson JC, Sanchez D, Johns AC, Campbell MT, Aydin AM, Gokden N, Maraboyina S, Muesse JL, Ward JF, Pisters LL, Zacharias NM, Guo CC, Tu SM. Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer. J Clin Med 13(12), 2024. e-Pub 2024. PMID: 38929965.
30. Matin SF, Adibi M, Shah AY, Alhalabi O, Corn P, Guo C, Amirtharaj R, Xiao L, Lange S, Duose DY, Wang S, Pal S, Campbell MT. Phase 1b Trial Evaluating Tolerability and Activity of Targeted FGFR Inhibition in Localized Upper Tract Urothelial Carcinoma. J Urol 211(6):784-792, 2024. e-Pub 2024. PMID: 38573872.
31. Cho, WC, Saade, R, Nagarajan, P, Aung, PP, Milton, D, Marques-Piubelli, ML, Hudgens, CW, Ledesma, D, Nelson, KC, Ivan, D, Zhang, M, Torres Cabala, CA, Campbell, MT, Alhalabi, O, Prieto, V, Wistuba, II, Esmaeli, B, Curry, JL. Nectin-4 expression in a subset of cutaneous adnexal carcinomas. Journal of cutaneous pathology 51(5):360-367, 2024. e-Pub 2024. PMID: 38200650.
32. Campbell MT, Balderrama-Brondani V, Jimenez C, Tamsen G, Marcal LP, Varghese J, Shah AY, Long JP, Zhang M, Ochieng J, Haymaker C, Habra MA. Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial. Lancet Oncol 25(5):649-657, 2024. e-Pub 2024. PMID: 38608694.
33. Hahn AW, Surasi DS, Viscuse PV, Bathala TK, Wiele AJ, Campbell MT, Zurita AJ, Shah AY, Jonasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel P. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. Oncologist 29(5):392-399, 2024. e-Pub 2024. PMID: 38035767.
34. Jimenez C, Habra MA, Campbell MT, Tamsen G, Cruz-Goldberg D, Long J, Bassett R, Dantzer R, Balderrama-Brondani V, Varghese J, Lu Y. Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial. Lancet Oncol 25(5):658-667, 2024. e-Pub 2024. PMID: 38608693.
35. Paindelli C, Parietti V, Barrios S, Shepherd P, Pan T, Wang WL, Satcher RL, Logothetis CJ, Navone N, Campbell MT, Mikos AG, Dondossola E. Bone mimetic environments support engineering, propagation, and analysis of therapeutic response of patient-derived cells, ex vivo and in vivo. Acta Biomater 178:83-92, 2024. e-Pub 2024. PMID: 38387748.
36. Sood A, Rudzinski JK, Labbate CV, Hensley PJ, Bree KK, Guo CC, Alhalabi O, Campbell MT, Siefker-Radtke AO, Navai N, Dinney CPN, Gao J, Kamat AM. Long-Term Oncological Outcomes in Patients Diagnosed with Non-Metastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. J Urol 211(2):101097JU0000000000003778, 2024. e-Pub 2024. PMID: 37922370.
37. Gross-Goupil M, Bodnar L, Campbell MT, Venugopal B, Zolnierek J, Dutailly P, Procopio G, Albiges L. Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence. Clin Genitourin Cancer 22(1):84-97, 2024. e-Pub 2024. PMID: 38101983.
38. Moussa MJ, Campbell MT, Alhalabi O. Revisiting Treatment of Metastatic Urothelial Cancer: Where do Cisplatin and Platinum-Ineligibility Criteria Stand?. Biomedicines 12(3), 2024. e-Pub 2024. PMID: 38540132.
39. Balderrama-Brondani V, Griffin AM, Owen TJ, Merriman KW, Chahla BB, Varghese J, Jimenez C, Waguespack SG, Graham PH, Perrier ND, Fisher SB, Karam JA, Shah AY, Campbell MT, Hassan MM, Habra MA. Incidence and geographical distribution of adrenocortical carcinoma: Retrospective analysis of a state cancer registry. Endocr Pract 30(1):25-30, 2024. e-Pub 2023. PMID: 37858722.
40. Cho WC, Saade R, Nagarajan P, Aung PP, Milton DR, Marques-Piubelli ML, Hudgens C, Ledesma D, Nelson K, Ivan D, Zhang M, Torres-Cabala CA, Campbell MT, Alhalabi O, Prieto VG, Wistuba II, Esmaeli B, Curry JL. Nectin‐4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin Journal: Journal of Cutaneous Pathology, 2024. e-Pub 2024.
41. Kamat AM, Apolo AB, Babjuk M, Bivalacqua TJ, Black PC, Buckley R, Campbell MT, Compérat E, Efstathiou JA, Grivas P, Gupta S, Kurtz NJ, Lamm D, Lerner SP, Li R, McConkey DJ, Palou Redorta J, Powles T, Psutka SP, Shore N, Steinberg GD, Sylvester R, Witjes JA, Galsky MD. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol 41(35):JCO2300307, 2023. e-Pub 2023. PMID: 37793077.
42. Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol 6(6):611-620, 2023. e-Pub 2023. PMID: 37833193.
43. Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus 9(5):734-741, 2023. e-Pub 2023. PMID: 36863962.
44. Lazure P, Campbell MT, Augustyniak M, Jaimes EA, Bilen MA, Lemke EA, Cohen EP, Jacobs G. Identifying the Needs of Health Care Providers in Advanced First-Line Renal Cell Carcinoma: A Mixed-Methods Research. Clin Genitourin Cancer 21(4):e299-e308, 2023. e-Pub 2023. PMID: 37045712.
45. Tan WS, Tan MY, Alhalabi O, Campbell MT, Kamat AM, Gao J. Evolving systemic management of urothelial cancers. Curr Opin Oncol 35(3):186-199, 2023. e-Pub 2023. PMID: 36966497.
46. Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CG. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun 14(1):2684, 2023. e-Pub 2023. PMID: 37164948.
47. Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol 6(2):228-232, 2023. e-Pub 2023. PMID: 34789422.
48. Hensley PJ, Duan Z, Bree K, Sood A, Zhao H, Lobo N, Contieri R, Campbell MT, Guo CC, Navai N, Williams SB, Dinney CP, Kamat AM. Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship. Urol Oncol 41(2):108.e11-108.e17, 2023. e-Pub 2023. PMID: 36404232.
49. Moore, JA, Lehner, MJ, Anfossi, S, Datar, S, Tidwell, R, Campbell, MT, Shah, AY, Ward, JF, Karam, JA, Wood, CG, Pisters, LL, Calin, GA, Tu, S. Predictive capacity of a miRNA panel in identifying teratoma in post-chemotherapy consolidation surgeries. BJUI Compass 4(1):81-87, 2023. e-Pub 2023. PMID: 36569509.
50. Hensley PJ, Bree KK, Guo CC, Lobo N, Campbell MT, Pettaway CA, Kamat AM. Clinicopathologic Analysis of Inflammatory Myofibroblastic Tumors of the Urinary Bladder. BJU Int 130(5):604-610, 2022. e-Pub 2022. PMID: 34773684.
51. Labbate CV, Hensley PJ, Miest TS, Qiao W, Adibi M, Shah AY, Chery L, Papadopoulos J, Siefker-Radtke AO, Gao J, Guo CC, Czerniak BA, Navai N, Kamat AM, Dinney CP, Campbell MT, Matin SF. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol 40(10):454.e17-454.e23, 2022. e-Pub 2022. PMID: 35961847.
52. De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int 129(5):610-620, 2022. e-Pub 2022. PMID: 34228889.
53. Daher M, Varghese J, Gruschkus SK, Jimenez C, Waguespack SG, Bedrose S, Altameemi L, Bazerbashi H, Naing A, Subaiah V, Campbell MT, Shah AY, Zhang M, Sheth RA, Karam JA, Wood CG, Perrier ND, Graham PH, Lee JE, Habra MA. Temporal Trends in Outcomes in Patients with Adrenocortical Carcinoma: A Multidisciplinary Referral Center Experience. J Clin Endocrinol Metab 107(5):1239-1246, 2022. e-Pub 2022. PMID: 35092681.
54. Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med 14(641):eabm6420, 2022. e-Pub 2022. PMID: 35442707.
55. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 13(1), 2022. e-Pub 2022. PMID: 35413951.
56. Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun 13(1), 2022. e-Pub 2022. PMID: 35379845.
57. Adibi M, McCormick B, Economides MP, Petros F, Xiao L, Guo C, Shah A, Kamat AM, Dinney C, Navai N, Gao J, Siefker-Radtke A, Matin SF, Campbell MT. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer 20(2):176-182, 2022. e-Pub 2022. PMID: 35039231.
58. Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer 128(6):1194-1205, 2022. e-Pub 2022. PMID: 34882781.
59. Moore JA, Slack RS, Lehner MJ, Campbell MT, Shah AY, Zhang M, Guo CC, Ward JF, Karam JA, Wood CG, Pisters LL, Tu SM. Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267435.
60. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer 20(1):e16-e24, 2022. e-Pub 2022. PMID: 34362693.
61. Jimenez C, Xu G, Varghese J, Graham PH, Campbell MT, Lu Y. New Directions in Treatment of Metastatic or Advanced Pheochromocytomas and Sympathetic Paragangliomas: an American, Contemporary, Pragmatic Approach. Curr Oncol Rep 24(1):89-98, 2022. e-Pub 2022. PMID: 35061191.
62. Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke AO, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AY. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass 3(1):37-44, 2022. e-Pub 2022. PMID: 35475152.
63. Alhalabi O, Altameemi L, Campbell MT, Meric-Bernstam F. Recent Advances in the Development of Antibody-Drug Conjugates in Urothelial Cancer. Cancer J 28(6):417-422, 2022. e-Pub 2022. PMID: 36383903.
64. Johns AC, Campbell MT. Toxicities From Antibody-Drug Conjugates. Cancer J 28(6):469-478, 2022. e-Pub 2022. PMID: 36383910.
65. Pieretti AC, Shapiro DD, Westerman ME, Hwang H, Wang X, Segarra LA, Campbell MT, Tannir NM, Jonasch E, Matin SF, Wood CG, Karam JA. Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urol Oncol 39(12):837.e9-837.e17, 2021. e-Pub 2021. PMID: 34551888.
66. Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Reply by Authors. J Urol 206(5):101097JU000000000000194302, 2021. e-Pub 2021. PMID: 34372685.
67. Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo AB, Allison JP, Yadav SS, Sharma P. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun 12(1):6375, 2021. e-Pub 2021. PMID: 34737281.
68. Pieretti AC, Westerman ME, Childs A, Millward N, Shapiro DD, Sircar K, Rao P, Jonasch E, Campbell MT, Tannir NM, Matin SF, Wood CG, Karam JA. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol 39(11):790.e17-790.e23, 2021. e-Pub 2021. PMID: 34301458.
69. Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Progression of Disease after BCG Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol 206(5):101097JU0000000000001943, 2021. e-Pub 2021. PMID: 34184926.
70. Hahn AW, Chahoud J, Campbell MT, Karp DD, Wang J, Stephen B, Tu SM, Pettaway CA, Naing A. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Invest New Drugs 39(5):1405-1410, 2021. e-Pub 2021. PMID: 33770291.
71. Hahn A, Shah AY, Campbell MT. First-line immune-oncology combinations for metastatic clear cell renal cell carcinoma (mRCC): a systematic review of phase III clinical trials. Kidney Cancer, 2021. e-Pub 2021.
72. Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open 4(8):e2122998, 2021. e-Pub 2021. PMID: 34459906.
73. Tsimberidou AM, Vo HH, Subbiah V, Janku F, Piha-Paul S, Yilmaz B, Gong J, Naqvi MF, Tu SM, Campbell MT, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. Oncologist 26(7):558-e1098, 2021. e-Pub 2021. PMID: 33491277.
74. Galsky MD, Balar AV, Black PC, Campbell MT, Dykstra GS, Grivas P, Gupta S, Hoimes CJ, Lopez LP, Meeks JJ, Plimack ER, Rosenberg JE, Shore N, Steinberg GD, Kamat AM. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34266883.
75. Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. Journal for ImmunoTherapy of Cancer 9(7), 2021. e-Pub 2021. PMID: 34326169.
76. Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Outcomes of patients with intermediate- or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer 149(2):387-393, 2021. e-Pub 2021. PMID: 33739450.
77. Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA, Jonasch E, Shah AY, Campbell MT, Msaouel P, Tannir NM. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. Oncologist 26(6):476-482, 2021. e-Pub 2021. PMID: 33792094.
78. McNally MA, Vangipuram R, Campbell MT, Nagarajan P, Patel AB, Curry JL, Heberton M. Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma. JAAD Case Rep 10:82-84, 2021. e-Pub 2021. PMID: 33778141.
79. Laccetti AL, Garmezy B, Xiao L, Economides M, Venkatesan A, Gao J, Jonasch E, Corn P, Zurita-Saavedra A, Brown LC, Kao C, Kinsey EN, Gupta RT, Harrison MR, Armstrong AJ, George DJ, Tannir N, Msaouel P, Shah A, Zhang T, Campbell MT. Combination anti-angiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance and clinical outcomes. Cancer Med 10(7):2341-2349, 2021. e-Pub 2021. PMID: 33650321.
80. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes. Mol Cancer Res 19(3):395-402, 2021. e-Pub 2021. PMID: 33323389.
81. McGregor BA, Campbell MT, Xie W, Farah S, Bilen MA, Schmidt AL, Sonpavde GP, Kilbridge KL, Choudhury AD, Mortazavi A, Shah AY, Venkatesan AM, Bubley GJ, Siefker-Radtke AO, McKay RR, Choueiri TK. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer 127(6):840-849, 2021. e-Pub 2021. PMID: 33216356.
82. Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol 39(2):134.e9-134.e16, 2021. e-Pub 2021. PMID: 33187886.
83. Hahn, AW, Shah, AY, Campbell, MT. First-Line Immuno-Oncology Combinations for Metastatic Clear Cell Renal Cell Carcinoma (mRCC). Kidney Cancer 5(4):207-217, 2021. e-Pub 2021.
84. Viscuse PV, Marques-Piubelli ML, Heberton MM, Parra ER, Shah AY, Siefker-Radtke A, Gao J, Goswami S, Ivan D, Curry JL, Campbell MT. Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. Front Oncol 11:621591, 2021. e-Pub 2021. PMID: 33747934.
85. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
86. Westerman ME, Shapiro DD, Tannir NM, Campbell MT, Matin SF, Karam JA, Wood CG. Survival Following Cytoreductive Nephrectomy: A Comparison of Existing Prognostic Models. BJU Int 126(6):745-753, 2020. e-Pub 2020. PMID: 32623821.
87. Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, Mu XJ, Ching KA, Uemura M, Pal SK, Alekseev B, Gravis G, Campbell MT, Penkov K, Lee JL, Hariharan S, Wang X, Zhang W, Wang J, Chudnovsky A, di Pietro A, Donahue AC, Choueiri TK. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med 26(11):1733-1741, 2020. e-Pub 2020. PMID: 32895571.
88. Bedrose S, Miller KC, Altameemi L, Ali MS, Nassar S, Garg N, Daher M, Eaton KD, Yorio JT, Daniel DB, Campbell MT, Bible KC, Ryder M, Chintakuntlawar AV, Habra MA. Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 32737143.
89. Choueiri TK, Motzer R, Rini B, Haanen J, Campbell MT, Venugopal B, Kollmannsberger C, Gravis-Mescam G, Uemura M, Lee JL, Grimm MO, Gurney H, Schmidinger M, Larkin J, Atkins MB, Pal SK, Wang J, Mariani M, Krishnaswami S, Cislo P, Chudnovsky A, Fowst C, Huang B, di Pietro A, Albiges L. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Annals of Oncology. 2020 Accepted for publication. e-Pub 2020. PMID: 32339648.
90. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell MT, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Amir Habra M. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32188704.
91. Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist 25(3):252-258, 2020. e-Pub 2020. PMID: 32162795.
92. Alhalabi O, Campbell MT, Shah AY, Siefker-Radtke AO. Emerging treatments in advanced urothelial cancer. Current Opinion in Oncology, 2020. e-Pub 2020.
93. Economides MP, Shah AY, Jimenez C, Habra MA, Desai M, Campbell MT. A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature. Front Endocrinol (Lausanne) 11:594264, 2020. e-Pub 2020. PMID: 33329398.
94. Li R, Kukreja JEB, Seif MA, Petros FG, Campbell MT, Nguyen JV, González GMN, Kamat AM, Pisters LL, Dinney CP, Navai N. The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World J Urol 37(12):2691-2698, 2019. e-Pub 2019. PMID: 30864005.
95. Habra MA, Stephen B, Campbell MT, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer 7(1):253, 2019. e-Pub 2019. PMID: 31533818.
96. Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer 114:67-75, 2019. e-Pub 2019. PMID: 31075726.
97. Habra MA, Sukkari MA, Hasan A, Albousen Y, Elsheshtawi MA, Jimenez C, Campbell MT, Karam JA, Graham PH, Hatia RI, Phan AT, Varghese J, Hassan MM. Epidemiological risk factors for adrenocortical carcinoma: A hospital-based case-control study. Int J Cancer. e-Pub 2019. PMID: 31241762.
98. Alhalabi O, Rafei H, Shah AY, Siefker-Radtke A, Campbell MT, Gao J. Targeting advanced urothelial carcinoma-developing strategies. Curr Opin Oncol 31(3):207-215, 2019. e-Pub 2019. PMID: 30844889.
99. Lemke EA, Shah AY, Campbell MT, Tannir NM. Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis. J Adv Pract Oncol 10(4):333-339, 2019. e-Pub 2019. PMID: 33343982.
100. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380(12):1103-1115, 2019. e-Pub 2019. PMID: 30779531.
101. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 25(1):188, 2019. e-Pub 2019. PMID: 30479380.
102. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 24(12):1804-1808, 2018. e-Pub 2018. PMID: 30420754.
103. Campbell MT, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, Altinmakas E, Duran C, Msaouel P, Tannir NM. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. European Journal of Cancer 104:188-194, 2018. e-Pub 2018. PMID: 30380460.
104. Özdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. Eur Urol Focus 4(3):442-454, 2018. e-Pub 2018. PMID: 29056275.
105. Campbell MT, Shah AY, Matin SF, Siefker-Radtke AO. Optimizing management of upper tract urothelial carcinoma. Urol Oncol 35(7):492-498, 2017. e-Pub 2017. PMID: 28579283.
106. Metcalfe MJ, Ferguson JE, Li R, Xiao L, Guo CC, Czerniak BA, Siefker-Radtke A, Pretzsch SM, Navai N, McConkey DJ, Kamat AM, Campbell MT, Dinney C. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus. e-Pub 2017. PMID: 28753816.
107. Siefker-Radtke AO, Campbell MT. Reply to B. Biswas et al. J Clin Oncol 35(18):JCO2017732644, 2017. e-Pub 2017. PMID: 28471712.
108. Matrana MR, Baiomy A, Campbell MT, Alamri S, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Elsayes KM, Tannir NM. Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. Clin Genitourin Cancer 15(2):e205-e208, 2017. e-Pub 2017. PMID: 27568124.
109. Siefker-Radtke AO, Campbell MT. Now Is the Time for Perioperative Chemotherapy in Upper Tract Urothelial Cancer. J Clin Oncol 35(8):816-817, 2017. e-Pub 2017. PMID: 28165904.
110. Msaouel P, Bilen MA, Zhang M, Campbell MT, Wang J, Tu SM. Recent developments in the management of germ cell tumors. Curr Opin Oncol. e-Pub 2017. PMID: 28151756.
111. Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget 7(52):86280-86289, 2016. e-Pub 2016. PMID: 27861143.
112. Matrana MR, Bathala T, Campbell MT, Duran C, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Tannir NM. Outcomes of Unselected Patients with Metastatic Clear-Cell Renal Cell Carcinoma Treated with Front-Line Pazopanib Therapy Followed by Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors (VEGFR-TKI) or Mammalian Target of Rapamycin Inhibitors (mTORi): A Single Institution Experience. BJU Int 118(2):264-71, 2016. e-Pub 2016. PMID: 26573089.
113. Campbell MT, Jonasch E. Treatment of Relapsed Germ Cell Tumors: Time For Something New?. J Oncol Pract 12(5):449-50, 2016. e-Pub 2016. PMID: 27170695.
114. Siefker-Radtke AO, Campbell MT, Munsell MF, Harris DR, Carolla RL, Pagliaro LC. Front-line treatment with gemcitabine, paclitaxel and doxorubicin for patients with unresectable or metastatic urothelial cancer and poor renal function: Final results from a phase II study. Urology 89:83-9, 2016. e-Pub 2016. PMID: 26723185.
115. Campbell MT, Siefker-Radtke AO, Gao J. The state of Immune Check Point Inhibition in Urothelial Carcinoma: current Evidence and Future Areas of Exploration. Cancer J 22(2):96-100, 2016. e-Pub 2016. PMID: 27111904.
116. Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen SJ, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. Clin Genitourin Cancer 13(3):218-24, 2015. e-Pub 2015. PMID: 25465491.
117. Campbell SR, Campbell MT, Shah C, et al. Educational conference scheduling, patient discharge time, and resident satisfaction. Journal of Graduate Medical Education 6(3):574-576, 2014. e-Pub 2014.
118. Zhang H, Hile KL, Asanuma H, Vanderbrink B, Franke EI, Campbell MT, Meldrum KK. IL-18 mediates proapoptotic signaling in renal tubular cells through a Fas ligand-dependent mechanism. Am J Physiol Renal Physiol 301(1):F171-8, 2011. e-Pub 2011. PMID: 21511702.
119. Campbell MT, Hile KL, Zhang H, Asanuma H, Vanderbrink BA, Rink RR, Meldrum KK. Toll-like receptor 4: a novel signaling pathway during renal fibrogenesis. J Surg Res 168(1):e61-9, 2011. e-Pub 2011. PMID: 20089260.
120. Asanuma H, Vanderbrink BA, Campbell MT, Hile KL, Zhang H, Meldrum DR, Meldrum KK. Arterially delivered mesenchymal stem cells prevent obstruction-induced renal fibrosis. J Surg Res 168(1):e51-9, 2011. e-Pub 2011. PMID: 20850784.
121. Bani-Hani AH, Leslie JA, Asanuma H, Dinarello CA, Campbell MT, Meldrum DR, Zhang H, Hile K, Meldrum KK. IL-18 neutralization ameliorates obstruction-induced epithelial-mesenchymal transition and renal fibrosis. Kidney Int 76(5):500-11, 2009. e-Pub 2009. PMID: 19536084.
122. Campbell MT, Dagher P, Hile KL, Zhang H, Meldrum DR, Rink RC, Meldrum KK. Tumor necrosis factor-alpha induces intrinsic apoptotic signaling during renal obstruction through truncated bid activation. J Urol 180(6):2694-700, 2008. e-Pub 2008. PMID: 18951565.
123. Bani-Hani AH, Campbell MT, Meldrum DR, Meldrum KK. Cytokines in epithelial-mesenchymal transition: a new insight into obstructive nephropathy. J Urol 180(2):461-8, 2008. e-Pub 2008. PMID: 18550128.

Invited Articles

1. Campbell MT, Jonasch E. Updates in the Systemic Treatment of Patients with Metastatic Renal Cell Carcinoma. e-Pub 2016.

Manuals, Teaching Aids, Other Teaching Publications

1. Campbell MT, Choi SL, Corn P, Jonasch E, Karam J, Matin S, Ng CS, Nguyen Q, Tannir N, Wood C. Renal Cell Carcinoma treatment. The University of Texas MD Anderson Cancer Center, 2015.

Other Articles

1. Campbell MT, Sood A, Lim A, Yao H, Wei P, Narayan V, Lee I, Seif M, Bree K, Matulay J, Kamat A, Dinney C, Navai N Is pT0 a Reliable End Point for Biomarker Discovery for Preoperative Chemotherapy Response in Patients with Bladder Cancer. JU Open Plus 2(e00131), 2024.

Editorials

1. Campbell MT, Zhang T. Special Issue Editorial: Emerging Therapies in Renal Cell Carcinoma: The Road to a Cure?. Cancers (Basel) 15(21), 2023. PMID: 37958435.
2. Campbell MT, Zhang T. Emerging Therapies in Renal Cell Carcinoma:, 2023.
3. Campbell MT, Shah AY. Therapeutic Options for Metastatic Clear Cell Renal Cell Carcinoma: The Front Line and Beyond in Early 2020. ASCO Daily News, 2020.
4. Campbell, MT, Kamat, A. New Drug Development in Urothelial Cancer: An Explosion of Riches?. ASCO Daily News, 2017.
5. Campbell MT. Metastatic Renal Cell Carcinoma: Current Therapies and Mechanisms of Resistance. ASCO Daily News, 2016.

Abstracts

1. Dizman N, Adra N, Vaishampayan UN, Xiao L, Yuan Y, Campbell MT, Gao J, Zurita AJ, Jonasch E, Tannir NM, Shah AY, Msaouel P, Hahn AW. A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC), 2024. e-Pub 2024.
2. Moussa MJ, Wilson NR, Xiao L, Tabet GC, Gao J, Shah AY, Corn PG, Goswami S, Msaouel P, Tannir NM, Lee BH, Kamat AM, Adibi M, Dinney CPN, Hansel DE, Guo CC, Siefker-Radtke AO, Campbell MT, Alhalabi O. Prognostic factors of relapse in surgically resected small cell neuroendocrine carcinomas of the urothelial tract (SCNEC-URO), 2024. e-Pub 2024.
3. Varatharajalu K, Shatila M, Campbell MT, Kovitz CA, DuPont HL, Wang Y. First-line treatment of fecal microbiota transplantation for immune-mediated colitis, 2024. e-Pub 2024.
4. El Zarif T, Semaan K, Xie W, Nguyen CB, Fahey C, Zarba M, Zemankova A, Ebrahimi H, Procopio G, Stellato M, Buti S, Melichar B, Venugopal B, Karam JA, Campbell MT, Beckermann K, Alva AS, Pal SK, Heng DYC, Choueiri TK. First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma (RCC): An international multi-center study, 2024. e-Pub 2024.
5. Motzer RJ, Penkov K, Uemura H, Campbell MT, Kollmannsberger CK, Lee JL, Venugopal B, Van Den Eertwegh A, Negrier S, Gurney H, Albiges L, Berger R, Haanen J, Rini BI, Larkin J, Schmidinger M, Sander R, Wang J, Di Pietro A, Choueiri TK. Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial, 2024. e-Pub 2024.
6. Nguyen CB, Vaishampayan UN, Campbell MT, Hammers HJ, Brooks R, Solley T, Wood LM, Jonasch E, Alva AS. Phase 2 study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma (RCC): FORTUNE trial, 2024. e-Pub 2024.
7. Jindal T, Jiang CY, Alhlabi O, Nguyen C, Nizam A, Basu A, Bilen MA, Zakharia Y, Milowsky MI, Brown J, Kilari D, Emamekhoo H, Hoimes C, Khaki AR, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva A, Koshkin VS. Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study. e-Pub 2024.
8. Jiang CY, Hwang H, Jindal T, Qiao W, Epstein I, Nguyen C, Gupta S, Shah S, Bilen M, Milowsky M, Hoimes C, Kilari D, Zakharia Y, Emamekhoo H, Grivas P, Bellmunt J, Alva A, Koshkin V, Campbell MT, Alhalabi O. Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR) altered (alt) advanced urothelial cancer (aUC): analysis of UNITE database, 2024. e-Pub 2024.
9. Moussa MJ, Chen AH, Grana AK, Gao J, Shah AY, Corn PG, Tannir NM, Goswami S, Sharma P, Wang J, Aparicio A, Araujo JC, Kamat AM, Pettaway CA, Logothetis CJ, Siefker-Radtke AO, Campbell MT, Alhalabi O. Clinical Outcomes of Frontline Gem-FLP in Advanced Urachal and Non-Urachal Adenocarcinomas of the Genitourinary Tract: The MD Anderson Cancer Center (MDACC) Experience, 2024. e-Pub 2024.
10. Galsky MD, Grande E, Necchi A, Koontz M, Iyer G, Campbell MT, Drakaki A, Loriot Y, Sokolowksi K, Zhang W, Powles T. Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001; Trial in Progress, 2024. e-Pub 2024.
11. Nizam A, Jindal T, Jiang CY, Alhalabi O, Davidsohn M, Bakaloudi DR, Talukder R, Nguyen CB, Oh E, Taylor AK, Bilen MA, Basu A, Kilari D, Emamekhoo H, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS. Sacituzumab govitecan (SG) outcomes in patients (pts) with advanced urothelial carcinoma (aUC) and variant histology component (VH): analysis of the UNITE study, 2024. e-Pub 2024.
12. Moussa MJ, Naqvi SAA, Khandelwal J, Campbell MT, Aparicio A, Siddiqui BA, Bryce A, Singh P, Alhalabi O. Clinical Efficacy of Lurbinectedin in Metastatic Neuroendocrine Carcinomas of the Genitourinary Tract – Multi-Institutional Real-World Experience, 2024. e-Pub 2024.
13. Johns AC, Campbell MT, Gao M, Lim Z, Wang E, Hahn AW, Gao J, Shah AY, Msaouel P, Tannir NM. Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC): The MD Anderson Cancer Center (MDACC) experience, 2024. e-Pub 2024.
14. Jindal T, Kilari D, Alhalabi O, Nizam A, Khaki AR, Basu A, Barata PC, Bilen MA, Shah S, Zakharia Y, Milowsky MI, Bellmunt J, Emamekhoo H, Davis NB, Grivas P, Gupta S, Hoimes CJ, Campbell MT, Alva AS, Koshkin VS. Biomarkers of response to enfortumab vedotin (EV) in patients with advanced urothelial carcinoma (aUC): analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study, 2023. e-Pub 2023.
15. Wang J, Campbell MT, Shah AY, Goswami S, Msaouel P, Alhalabi O, Hahn AW, Kovitz CA, Jana BRP, Araujo JC, Gao J, Zurita AJ, Jonasch E, Corn PG, Tannir NM. A Phase II Study of Nivolumab with Ipilimumab and Cabozantinib in Patients with Untreated Renal Cell Carcinoma Brain Metastases, 2023. e-Pub 2023.
16. Koshkin VS, Henderson N, Kilari D, Jindal T, Alhalabi O, Freeman D, Basu A, Barata P, Bilen M, Zakharia Y, Emamekhoo H, Shah S, Milowsky M, Davis N, Gupta S, Hoimes C, Grivas P, Bellmunt J, Campbell MT, Alva A. Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC), 2023. e-Pub 2023.
17. Shah NJ, Campbell MT, Mao SS, Ornstein MC, Haas NB, Keshava-Prasad H, Hammers HJ, Gao X, Yan H, Esquibel V, Geller RB, Beckermann K. A Phase 1b/2 study of Batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC), 2023. e-Pub 2023.
18. Campbell MT, Lazure P, Augustyniak M, Jaimes EA, Bilen MA, Lemke E, Jacobs G, McFadden P. Mixed methods assessment of providers’ needs in the management of advanced renal cell carcinoma, 2022. e-Pub 2022.
19. Shah N, Beckermann K, Vogelzang N, Mao S, Ornstein M, Hammers H, Gao X, McDermott D, Haas N, Esquibel V, Rangwala R, Campbell MT. A Phase 1b/2 study of Batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma who have received front-line treatment (NCT04300140), 2022. e-Pub 2022.
20. De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation 129(5):610-620, 2022. e-Pub 2022. PMID: 34228889.
21. McGregor B, Xie W, Bilen M, Campbell MT, Mortazavi A, HuangJ, Sunkara R, Ravi P, Shah A, Baca S, Sonpavde G, Bellmunt J, Siefker-Radtke A, Signoretti S, Van Allen E, Beltran H, McKay R, Choueiri T. Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation, 2022. e-Pub 2022.
22. Alhalabi O, Wilson N, Lianchun X, Navai N, Kamat A, Shah AY, Araujo J, Jianbo W, Goswami S, Gao J, Jennifer W, Guo C, Czerniak B, Corn P, Logothetis C, Dinney C, Campbell MT, Tannir, N. Factors associated with improved outcomes in surgically resectable small cell urothelial cancer (SCUC), 2022. e-Pub 2022.
23. Alhalabi O, Wilson, N, Lehner M, Ajufo H, Hasanov E, Campbell MT, Shah AY, Jennifer W, Jonasch E, Araujo J, Jianbo W, Gao J, Goswami S, Msaouel P, Tannir N. Safety and differential clinical activity of nivolumab plus ipilimumab (nivo-ipi) in patients (pts) with non-clear cell renal cell carcinoma (nccRCC), 2022. e-Pub 2022.
24. Karam J, Msaouel P, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Haymaker CL, Marmonti E, Duose D, Parra ER, Soto LMS, Laberiano C, Lozano M, Abraham A, Hallin M, Olson PD, Der-Torossian HD, Tannir NM, Wood CG. A Phase 2 Study of Sitravatinib (Sitra) in Combination With Nivolumab (Nivo) in Patients (Pts) Undergoing Nephrectomy for Locally-Advanced Clear Cell Renal Cell Carcinoma (accRCC), 2021. e-Pub 2021.
25. Andreev-Drakhlin AY, Shah AY, Andriazola A, Shaw L, Lopez L, James M, Matin SF, Alhalabi O, Gao J, Goswami S, Xiao L, Venkatesan AM, Campbell MT. Phase 1/1B trial of Sitravatinib (Sitra) + Nivolumab (Nivo) + Ipilimumab (Ipi) in Patients (pts) with Advanced Clear Cell Renal Cell Carcinoma (accRCC) or Other Solid Malignancies, 2021. e-Pub 2021.
26. Campbell MT, Economides MP, Shah AY, Habra M, Jimenez C, Desai M. A Durable Response with the Combination of Nivolumab and Cabozantinib in a Patient with Metastatic Paraganglioma: A case report and review of the current literature, 2020. e-Pub 2020.
27. Campbell MT, Sharma P, Singh S. A pilot study of Tremelimumab with or without cryoablation in patients with metastatic renal cell carcinoma (mRCC): a post hoc analysis of patients with clear cell (cc) versus non-clear cell (ncc) histologies, 2020. e-Pub 2020.
28. Voss MH, Motzer RJ, Albiges L, Rini BI, Schmidinger M, Larkin JMG, Haanen JB, Kollmannsberger CK, Campbell MT, Grill MO, Pal SK, Gravis G, Atkins MB, Huang B, Chudnovsky A, DiPietro A, Thomaidou D, Choueiri T. Depth of response analysis and correlation with clinical outcomes from Javelin Renal 101, 2020. e-Pub 2020.
29. Pavlos, M, Thall PF, Yuan Y, Wang X, Jonasch E, Gao JJ, Campbell MT, Shah AY, Corn PG, Tam A, Ahrar K, Rao P, Sircar K, Der-Torossian H, Tannir N. A phase I/II trial of sitravantinub combined with nivolumab in patients wutg advanced clear cell renal cell cancer that progressed on prior VEGF- targeted therapy, 2020. e-Pub 2020.
30. Voss MH, Motzer RJ, Albiges L, Rini BI, Schmidinger M, Larkin J, Haanen J, Kollmannsberger C, Campbell MT, Grimm MO, Pal SK, Gravis G, Atkins MB, Huang B, Chudnovsky A, Pietro D, A. Depth of response analysis and correlation with clinical outcomes from Javelin Renal 101, 2020. e-Pub 2020.
31. Choi S, Campbell MT, Shah AY, Navai N, Kamat AM, Dinney C, Nguyen Q, Siefker-Radtke AO. Prophylactic cranial irradiation (PCI) significantly decreases risk of brain metastases in patients with bulky, higher stage small-cell urothelial cancer 37(7S), 2019. e-Pub 2019.
32. Laccetti, Campbell MT, Economides, Gao, Jonasch, Corn, Zurita, Tannir, Msaouel, Shah A. Combination anti-angiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes 37(7S), 2019. e-Pub 2019.
33. Shah A, Lemke E, Gao J, Chandramohan A, Campbell MT, Zurita AJ, Xiao L, Wang J, Corn PG, Jonasch E, Sharma P, Tannir NM. Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors 37(7s), 2019. e-Pub 2019.
34. Choueiri TK, Motzer RJ, Campbell MT, Alekseev BY, Uemura M, Kollmannsberger CK, Gravis G, Bjarnason GA, Gurney H, Chung J, Haanen J, Rini BI, Larkin J, Schmidinger M, Nole F, Chudnovsky A, Huang B, Hariharan S, di Pietro A, Albiges L. Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) 37(7S), 2019. e-Pub 2019.
35. Alhalabi O, Campbell MT, Slack-Tidwell R, Siefker-Radtke AO, Shah AY, Efstathiou E, Wang WL, Titus MA, Czerniak B, Zhang M, Guo C, Logothetis C, Gao J. A phase II trial to evaluate pemetrexed clinical responses in relation to tumor methylthioadenosine phosphorylase (MTAP) gene status in patients with previously treated metastatic urothelial carcinoma 37(7s), 2019. e-Pub 2019.
36. Matulay JT, Campbell MT, Narayan VM, Seif MA, Lim AH, Shah AY, Pavlos M, Gao JJ, Siefker-Radtke AO, Dinnery CPN, Kamat AM, Navai N. Pathologic Outcomes after Neoadjuvant Chemotherapy for High-risk Muscle Invasive Bladder Cancer, 2019. e-Pub 2019.
37. Campbell MT, Xie W, Shah AY, Habra MA, Jimenez C, Venkatesan A, Killbridge KL, Bubley G, Mortazavi A, Bilen MA, McKay R, Choueiri TK, McGregor BA. Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastaic Adrenal Tumors, 2019. e-Pub 2019.
38. Campbell MT. Agnostic Transcriptional Profiling of The Cancer Genome Atlas Data Identifies Distinct and Cooperative Role of TP63 Isoforms in Renal Cancer Subtypes That Drive Progression and Predict Clinical Outcomes, 2019. e-Pub 2019.
39. Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood C, Tannir, N, Jonasch E, Gao JJ, Zurita A, Shah AY, Blando J, Duan F, Basu S, Yadav SS, Allison JP, Sharma P. A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC)), 2019. e-Pub 2019.
40. Campbell, MT. Comparing cabozantinib (C) treatment for a cohort of patients with metastatic clear cell (ccRCC) and variant histology renal cell carcinoma (vhRCC): a retrospective study 36(6S), 2018. e-Pub 2018.
41. Lemke E, Shah AY, Chandramohan A, Campbell MT, VanAlstine M, Jonasch E, Tannir NM. Real-world experience with cabozantinib in metastatic clear cell renal cell carcinoma (mccRCC) 36(6S), 2018. e-Pub 2018.
42. Li R, Kukreja JB, Petros FG, Campbell MT, Nguyen J, Nogueras-Gonzalez GM, Kamat AM, Pisters LL, Dinney C, Navai N. The role of metastatic burden in cytoreductive/consolidative radical cystectomy 36(6S), 2018. e-Pub 2018.
43. Shah A, Lemke E, Gao J, Chandramohan A, Campbell MT, Zurita AJ, Xiao L, Wang J, Corn PG, Jonasch E, Sharma P, Tannir NM. Outcomes of patients (pts) with metastatic clear-cell renal cell carcinoma (mCCRCC) treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitors (ICI) 36(6S), 2018. e-Pub 2018.
44. Habra MA, Campbell MT, Jimenez C, Karp D, Hong D, Subbiah V, Pant S, Painter J, Khan S, Bernatchez C, Stephen B, Alshawa A, Tapia C, Mendoza T, Colen R, Hess K, Meric-Bernstam F, Naing A. Efficacy of Pembrolizumab (MK-3475) in Patients with Adrenocortical Carcinoma, 2017. e-Pub 2017.
45. Campbell MT, Bilen MA, Duran C, Altinmakas E, Lim ZD, Jonasch E, Tannir NM. Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma (vhRCC): a retrospective study 28(28):5, 2017. e-Pub 2017.
46. Shah A, Lemke E, Gao J, Chandramohan A, Campbell MT, Zurita AJ, Xiao L, Wang J, Corn PG, Jonasch E, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma (mRCC) who were treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitor (ICI) therapy 28(25), 2017. e-Pub 2017.
47. Campbell MT, Bilen Mehmet A, Duran C, Altinmakas E, Lim ZD, Jonasch E, Tannir N. Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma(vhRCC): a retrospective study, 2017. e-Pub 2017.
48. Campbell MT, Bilen MA, Duran C, Altinmakas E, Lim ZD, Jonasch E, Tannir NM. Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma(vhRCC): a retrospective study. Genitourinary Cancer Symposium 2017 - Journal of Clinical Oncology 35(suppl 6S; abstract 478), 2017. e-Pub 2017.
49. Campbell MT, Matin SF, Slack B, Sun JJ, Chen H, NG Tang D, Zhang L, Rao P, Sharma P. Thermal ablation induces local and systemic immune changes in patients with metastatic renal cell carcinoma, 2017. e-Pub 2017.
50. Campbell MT, Matin SF, Slack B, Sun JJ, Chen H, NG Tang D, Zhang L, Rao P, Sharma P. Ablative Therapy to Induce local and systemic changes in patients with metastatic renal cell carcinoma, 2017. e-Pub 2017.
51. Gao JJ, Karam JA, Wood CG, Matin S, Ahrar K, Jonasch E, Tannir N, Campbell MT, Ng C, Slack R, Rao P, Allison JP, Blando JM, Vence LM, Basu S, Zhao H, Chen T, Chen H, Sharma P. Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma, 2017. e-Pub 2017.
52. Nieto Y, Tu SM, Campbell MT, Bassett R, Tannir N, Ward J, Hofstetter W, Jones RB, Andersson BS, Gulbis A, Ledesma C, Timmons M, Trapp M, Champlin R, Pagliaro L. Infusional Gemcitabine + Docetaxel/melphalan/Carboplatin (GemDMC) + Bevacizumab (BEV) is an Effective High-Dose Chemotherapy (HDC) Regimen for Refractory of Pro-Risk Relapsed Germ-Cell Tumors (GCT), 2017. e-Pub 2017.
53. Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Rao P, Zhang M, General R, Cauley DH, Lin SH, Pisters LL, Tu SM. Intratumoral hterogeneity and chemo-resistance in nonseminomatous germ cell tumor of the testis, 2016. e-Pub 2016.
54. Campbell MT, McConkey DJ, Matina SF, Kamat AM, Dinney CP, Wang J, Gao JJ, Siefker-Radtke AO. The hotspot mutational landscape of upper tract and bladder urothelial cancers and correlation to survival. Genitourinary Cancer Symposium 2016 - Journal of Clinical Oncology 34(suppl 2S; abstr 466), 2016. e-Pub 2016.
55. Campbell MT, Shah AY, Nautiyal KD, Hashemi N, Corn PG, Pagliaro LC, Jonasch E, Tannir NM. Association of chronic co-morbidities with long term survival with metastatic renal cell carcinoma (mRCC). Genitourinary Cancer Symposium 2015 - Journal of Clinical Oncology 33(suppl 7), 2015. e-Pub 2015.
56. Shah AY, Campbell MT, Nautiyal KD, Neda H, Matin SF, Vaporciyan AA, Rhines LD, Moon B, Lewis VO, Lin PP, Prabhu SS, Rao G, Corn PG, Pagliaro LC, Mehran RJ, Wood CJ, Jonasch E, Tannir NM. Long-term survivorship in patients with metastatic renal cell cancer (mRCC) managed with metastasectomy: A retrospective study from the MD Anderson Cancer Center (MDACC). Genitourinary Cancer Symposium 2015 - Journal of Clinical Oncology 33(suppl 7), 2015. e-Pub 2015.
57. Campbell MT, Shah AY, Hashemi N, Nautiyal KD, Corn PG, Pagliaro LC, Jonasch E, Tannir NM. Long-term survivorship in patients (pts) with metastatic renal cell cancer (mRCC): A retrospective study from the MD Anderson Cancer Center (MDACC). Genitourinary Cancer Symposium 2015 - Journal of Clinical Oncology 33(suppl 7):suppl 7, 2015. e-Pub 2015.
58. Campbell MT, Millikan R, Emre A, Xiao L, Tannir NM. Phase I trial of sunitinib (S) and temsirolimus (T) in metastatic renal cell carcinoma (mRCC). Genitourinary Cancer Symposium 2014 - Journal of Clinical Oncology 32(suppl 4), 2014. e-Pub 2014.
59. Campbell MT, Jung J, Philips S, Mohammadi Y, Carr KA, Davis TL, Li L, Sweeney CJ, Skaar TC. Germline single nucleotide polymorphism (SNP) predictors of progression free survival and overall survival in advanced prostate cancer patients treated with androgen deprivation therapy (ADT). Poster presented at: Genitourinary American Society of Clinical Oncology Meeting; Orlando, FL, 2011. e-Pub 2011.
60. Campbell MT, Hile K, Zhang H, Asanuma H, Rink R, Meldrum KK. Toll-like receptor 4: a novel signaling pathway during renal fibrogenesis. Poster presented at: American Academy of Pediatrics National Meeting; Boston, MA, 2008. e-Pub 2008.
61. Trikannad A, Vellanki S, Joon AY, Estecio MR, Johns AC, Campbell MT, Sanchez D, Ward JF, Pisters LL, Zhang M, Guo CC, Zacharias NM, Tu SM. Subsequent Malignant Neoplasms (SMN) in Patients with Germ Cell Tumor of the Testis (TGCT): Implications on a Genetic vs Stem Cell Origin of Cancers.
62. Motzer RJ, Penkov K, Uemura H, Campbell MT, Kollmannsberger C, Lee JL, Venugopal B, Van den Eertwegh A, Negrier S, Gurney H, Albiges L, Berger R, Haanen JAG, Rini BI, Larkin J, Schmidinger M, Laliberte R, Wang J, DiPietro A, Choueiri TK. Avelumab + axitinib vs sunitinib in patients with advanced renal cell carcinoma (aRCC): final analysis of overall survival (OS) from the JAVELIN Renal 101 phase 3 trial.

Book Chapters

1. Campbell MT, Karam JA, Logothetis CJ. Cancer of the Testis. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 12th Edition, 2023.
2. Lee JE, Habra MA, Campbell MT. Malignant tumors of the adrenal gland. In: Cancer Medicine. Tenth, 2023.
3. Sharma, A, Campbell MT, Yee, C, Goswami, S, Sharma, P. Immunotherapy of Cancer. In: Clinical Immunology, 2019.
4. Campbell MT, Karam J, Logothetis C. Testicular Cancer. In: Cancer Medicine. 9, 2017.
5. Campbell MT, Sharma A, Goswami S, Sharma P. Tumor Immunotherapy. In: Clinical Immunology: Principles and Practice, 5th Edition, 2016.
6. Campbell MT, Jonasch E, Wood CG, Tannir NM. Renal Cell Carcinoma. In: The MD Anderson Manual of Medical Oncology. Third Edition, 2016.

Letters to the Editor

1. Shanker, MD, Yu, ZH, Yang, J, Matin, S, Campbell, M, Msaouel, P, Tannir, NM, Prajapati, S, Ding, Y, Lee, B, Sobremonte, A, Tang, C. MR-Linac-guided stereotactic radiotherapy for CT-indiscernible intravascular renal cell carcinoma tumours. BJUI Compass 5: 913-915, 2024.